Tonix Data Reveals Opioid Overuse in Fibromyalgia Despite Guidelines

At the 2026 American Society of Clinical Psychopharmacology Annual Meeting, Tonix Pharmaceuticals (NASDAQ: TNXP) revealed alarming data: opioid use remains widespread among U.S. adults with fibromyalgia, despite long-standing guidelines advising against it. Analyzing over 261,000 patients from the Symphony Health claims database, the study found that roughly 40% of commercially insured, Medicare Advantage, and Medicaid fibromyalgia patients received at least one opioid prescription, with tramadol and oxycodone being the most common. Tonix emphasized that this gap between clinical practice and evidence-based recommendations underscores the urgent need for greater awareness of FDA-approved, non-opioid alternatives like TONMYA(R), the company’s recently approved fibromyalgia therapy.

Tonix Pharmaceuticals is a fully integrated commercial-stage biotech firm concentrating on central nervous system (CNS) and immunology treatments for high unmet medical needs. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new fibromyalgia treatment in over 15 years. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is also exploring TONMYA’s potential in Phase 2 trials for major depressive disorder and acute stress disorder. Additionally, its pipeline includes TNX-2900 (Phase 2 ready for Prader-Willi syndrome), monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.

Tonix’s findings highlight a critical public health issue: despite evidence-based guidelines, opioids are still frequently prescribed for fibromyalgia, a condition for which non-opioid treatments exist. The full press release is available at https://ibn.fm/6AtjR. For more updates on TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.